Evaluating home injection compared with healthcare-setting injection of somatostatin analogs: a systematic literature review

Cesar L. Boguszewski; Márta Korbonits; Audrey Artignan; Almudena Martín García; Aude Houchard; Antonio Ribeiro-Oliveira; Wouter W. de Herder

doi:10.1007/s12020-022-03227-0

Evaluating home injection compared with healthcare-setting injection of somatostatin analogs: a systematic literature review

Cesar L. Boguszewski^*
, Márta Korbonits
, Audrey Artignan
, Almudena Martín García
, Aude Houchard
, Antonio Ribeiro-Oliveira
, Wouter W. de Herder

^*Corresponding author for this work

Internal Medicine

Universidade Federal do Paraná
Barts and The London School of Medicine and Dentistry
Costello Medical
Ipsen

Research output: Contribution to journal › Article › Academic › peer-review

8 Citations (Scopus)

Abstract

Purpose: A systematic literature review was conducted to assess the use of home injections (self/partner/healthcare provider [HCP]-administered) of somatostatin analogs (SSAs) as an alternative to healthcare-setting injections in patients with acromegaly and neuroendocrine tumors (NETs). Methods: MEDLINE/Embase/the Cochrane Library (2001–September 2021), key congresses (2019–2021), and bibliographies of relevant systematic reviews were searched. Eligible studies reported on efficacy/effectiveness, safety, adherence, patient-reported outcomes (PROs), and economic outcomes in populations receiving home injections of SSAs. Results: Overall, 12 studies were included, all reporting on SSAs (lanreotide Autogel/Depot or octreotide long-acting release) in acromegaly or NETs. Across four studies, home injection was associated with similar disease control in patients with acromegaly/NETs compared with healthcare-setting administration. High rates of treatment adherence were shown in two studies of patients with acromegaly receiving lanreotide injections at home. Two studies reported non-serious adverse events; incidence of adverse reactions was similar in both the home and healthcare administration settings. Preference for injection setting varied between studies and indications; nonetheless, higher satisfaction/convenience (>75% patients) was reported for home injections. Self- or partner-injection was associated with economic savings compared with administration in the healthcare setting across five studies. Conclusion: Efficacy/effectiveness, adherence, and safety outcomes of SSAs in the home injection setting were similar to those in the healthcare setting, with high reported satisfaction and convenience. Self/partner injection also resulted in cost savings. These findings provide a basis to understand outcomes related to home injection and encourage healthcare providers to discuss optimal treatment choices with their patients.

Original language	English
Pages (from-to)	527-536
Number of pages	10
Journal	Endocrine
Volume	79
Issue number	3
Early online date	11 Nov 2022
DOIs	https://doi.org/10.1007/s12020-022-03227-0
Publication status	Published - Mar 2023

Bibliographical note

Funding Information:
This work was sponsored by Ipsen Biopharmaceuticals, Inc. Support for third-party writing assistance for this article was funded by Ipsen in accordance with Good Publication Practice (GPP3) guidelines ( http://www.ismpp.org/gpp3 ).

Publisher Copyright:
© 2022, The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1007/s12020-022-03227-0

Cite this

@article{7802e1cdcc9e4cae92d5e6d4d982bf0b,

title = "Evaluating home injection compared with healthcare-setting injection of somatostatin analogs: a systematic literature review",

abstract = "Purpose: A systematic literature review was conducted to assess the use of home injections (self/partner/healthcare provider [HCP]-administered) of somatostatin analogs (SSAs) as an alternative to healthcare-setting injections in patients with acromegaly and neuroendocrine tumors (NETs). Methods: MEDLINE/Embase/the Cochrane Library (2001–September 2021), key congresses (2019–2021), and bibliographies of relevant systematic reviews were searched. Eligible studies reported on efficacy/effectiveness, safety, adherence, patient-reported outcomes (PROs), and economic outcomes in populations receiving home injections of SSAs. Results: Overall, 12 studies were included, all reporting on SSAs (lanreotide Autogel/Depot or octreotide long-acting release) in acromegaly or NETs. Across four studies, home injection was associated with similar disease control in patients with acromegaly/NETs compared with healthcare-setting administration. High rates of treatment adherence were shown in two studies of patients with acromegaly receiving lanreotide injections at home. Two studies reported non-serious adverse events; incidence of adverse reactions was similar in both the home and healthcare administration settings. Preference for injection setting varied between studies and indications; nonetheless, higher satisfaction/convenience (>75\% patients) was reported for home injections. Self- or partner-injection was associated with economic savings compared with administration in the healthcare setting across five studies. Conclusion: Efficacy/effectiveness, adherence, and safety outcomes of SSAs in the home injection setting were similar to those in the healthcare setting, with high reported satisfaction and convenience. Self/partner injection also resulted in cost savings. These findings provide a basis to understand outcomes related to home injection and encourage healthcare providers to discuss optimal treatment choices with their patients.",

author = "Boguszewski, \{Cesar L.\} and M{\'a}rta Korbonits and Audrey Artignan and Garc{\'i}a, \{Almudena Mart{\'i}n\} and Aude Houchard and Antonio Ribeiro-Oliveira and \{de Herder\}, \{Wouter W.\}",

note = "Funding Information: This work was sponsored by Ipsen Biopharmaceuticals, Inc. Support for third-party writing assistance for this article was funded by Ipsen in accordance with Good Publication Practice (GPP3) guidelines ( http://www.ismpp.org/gpp3 ). Publisher Copyright: {\textcopyright} 2022, The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.",

year = "2023",

month = mar,

doi = "10.1007/s12020-022-03227-0",

language = "English",

volume = "79",

pages = "527--536",

journal = "Endocrine",

issn = "1355-008X",

publisher = "Springer",

number = "3",

}

TY - JOUR

T1 - Evaluating home injection compared with healthcare-setting injection of somatostatin analogs

T2 - a systematic literature review

AU - Boguszewski, Cesar L.

AU - Korbonits, Márta

AU - Artignan, Audrey

AU - García, Almudena Martín

AU - Houchard, Aude

AU - Ribeiro-Oliveira, Antonio

AU - de Herder, Wouter W.

N1 - Funding Information: This work was sponsored by Ipsen Biopharmaceuticals, Inc. Support for third-party writing assistance for this article was funded by Ipsen in accordance with Good Publication Practice (GPP3) guidelines ( http://www.ismpp.org/gpp3 ). Publisher Copyright: © 2022, The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

PY - 2023/3

Y1 - 2023/3

N2 - Purpose: A systematic literature review was conducted to assess the use of home injections (self/partner/healthcare provider [HCP]-administered) of somatostatin analogs (SSAs) as an alternative to healthcare-setting injections in patients with acromegaly and neuroendocrine tumors (NETs). Methods: MEDLINE/Embase/the Cochrane Library (2001–September 2021), key congresses (2019–2021), and bibliographies of relevant systematic reviews were searched. Eligible studies reported on efficacy/effectiveness, safety, adherence, patient-reported outcomes (PROs), and economic outcomes in populations receiving home injections of SSAs. Results: Overall, 12 studies were included, all reporting on SSAs (lanreotide Autogel/Depot or octreotide long-acting release) in acromegaly or NETs. Across four studies, home injection was associated with similar disease control in patients with acromegaly/NETs compared with healthcare-setting administration. High rates of treatment adherence were shown in two studies of patients with acromegaly receiving lanreotide injections at home. Two studies reported non-serious adverse events; incidence of adverse reactions was similar in both the home and healthcare administration settings. Preference for injection setting varied between studies and indications; nonetheless, higher satisfaction/convenience (>75% patients) was reported for home injections. Self- or partner-injection was associated with economic savings compared with administration in the healthcare setting across five studies. Conclusion: Efficacy/effectiveness, adherence, and safety outcomes of SSAs in the home injection setting were similar to those in the healthcare setting, with high reported satisfaction and convenience. Self/partner injection also resulted in cost savings. These findings provide a basis to understand outcomes related to home injection and encourage healthcare providers to discuss optimal treatment choices with their patients.

AB - Purpose: A systematic literature review was conducted to assess the use of home injections (self/partner/healthcare provider [HCP]-administered) of somatostatin analogs (SSAs) as an alternative to healthcare-setting injections in patients with acromegaly and neuroendocrine tumors (NETs). Methods: MEDLINE/Embase/the Cochrane Library (2001–September 2021), key congresses (2019–2021), and bibliographies of relevant systematic reviews were searched. Eligible studies reported on efficacy/effectiveness, safety, adherence, patient-reported outcomes (PROs), and economic outcomes in populations receiving home injections of SSAs. Results: Overall, 12 studies were included, all reporting on SSAs (lanreotide Autogel/Depot or octreotide long-acting release) in acromegaly or NETs. Across four studies, home injection was associated with similar disease control in patients with acromegaly/NETs compared with healthcare-setting administration. High rates of treatment adherence were shown in two studies of patients with acromegaly receiving lanreotide injections at home. Two studies reported non-serious adverse events; incidence of adverse reactions was similar in both the home and healthcare administration settings. Preference for injection setting varied between studies and indications; nonetheless, higher satisfaction/convenience (>75% patients) was reported for home injections. Self- or partner-injection was associated with economic savings compared with administration in the healthcare setting across five studies. Conclusion: Efficacy/effectiveness, adherence, and safety outcomes of SSAs in the home injection setting were similar to those in the healthcare setting, with high reported satisfaction and convenience. Self/partner injection also resulted in cost savings. These findings provide a basis to understand outcomes related to home injection and encourage healthcare providers to discuss optimal treatment choices with their patients.

UR - https://www.scopus.com/pages/publications/85141758711

U2 - 10.1007/s12020-022-03227-0

DO - 10.1007/s12020-022-03227-0

M3 - Article

C2 - 36369434

AN - SCOPUS:85141758711

SN - 1355-008X

VL - 79

SP - 527

EP - 536

JO - Endocrine

JF - Endocrine

IS - 3

ER -

Evaluating home injection compared with healthcare-setting injection of somatostatin analogs: a systematic literature review

Abstract

Bibliographical note

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this